We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





US Labs Increase COVID-19 Testing Capacity but Facing Shortage of Supplies, Finds NILA Survey

By LabMedica International staff writers
Posted on 06 Oct 2020
A survey of community and regional laboratories in the US has revealed a potential collective increase in COVID-19 testing capacity, although difficulties persist in accessing the necessary testing supplies. More...


The National Independent Laboratory Association (NILA St. Louis, MO, USA) conducted a survey of 12 twelve community and regional laboratories that revealed shortages of test kits, reagents, and other materials, such as plastic pipette tips, without which they were unable to perform the promised number of tests. In spite of an increase in their COVID-19 testing capacity, these labs do not have access to the supplies and materials necessary to perform critical COVID-19 tests. For example, one regional laboratory reported an allocation from a manufacturer of enough reagents to process 500 tests per day, although it has a capacity for performing at least 3,000 tests per day.

The NILA has stressed that speedy test results are critical for isolating infected patients and mitigating the spread of COVID-19. Community and regional laboratories report they can provide test results within one to two days which is significantly faster than the reported wait times experienced by most of the US population in recent weeks and months. According to the NILA, mitigating supply shortages will help increase the number of tests provided as well as the speed with which test results are delivered.

“The federal government must do whatever it can to help alleviate the testing supply shortages NILA members are experiencing,” said Mark Birenbaum, Ph.D., executive director, NILA. “We won’t emerge from this pandemic unless we focus on testing, and community and regional independent laboratories are key to scaling up our nation’s testing capacity. We have not seen transparency from the federal government regarding where test supplies are being allocated and how community labs can increase their access to these essential supplies.”

Related Links:
National Independent Laboratory Association


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.